Compare ELUT & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELUT | DARE |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.3M | 24.4M |
| IPO Year | 2020 | N/A |
| Metric | ELUT | DARE |
|---|---|---|
| Price | $0.95 | $1.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $7.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 275.6K | 76.0K |
| Earning Date | 03-05-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $21,746,000.00 | N/A |
| Revenue This Year | N/A | $3,843.33 |
| Revenue Next Year | N/A | $8,700.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.08 | N/A |
| 52 Week Low | $0.50 | $1.61 |
| 52 Week High | $3.46 | $9.19 |
| Indicator | ELUT | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 56.14 | 37.75 |
| Support Level | $0.85 | $1.68 |
| Resistance Level | $1.04 | $1.77 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 35.96 | 15.63 |
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.